TKT to Present at Two Upcoming Healthcare Conferences
March 24 2005 - 9:30AM
PR Newswire (US)
TKT to Present at Two Upcoming Healthcare Conferences CAMBRIDGE,
Mass., March 24 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that it will present at two
upcoming conferences on Thursday, March 31, 2005: Smith Barney
Citigroup's 2005 Healthcare Conference being held March 29-31, 2005
in Washington, D.C. and Lehman Brothers' Eighth Annual Healthcare
Conference being held March 30- April 1, 2005 in Miami, Florida.
Michael J. Astrue, President and Chief Executive Officer, will
present an overview of TKT's business activities and product
pipeline at the Citigroup conference on Thursday, March 31, 2005 at
10:20 a.m. Eastern Time. David D. Pendergast, Ph.D., Executive Vice
President and Chief Operating Officer will present an overview of
TKT's business activities and product pipeline at the Lehman
Brothers conference on Thursday, March 31, 2005 at 3:15 p.m.
Eastern Time. A live audio webcast of these presentations will be
available at http://www.tktx.com/ on TKT's Investor Information
website under the Events category. A replay will be available for
approximately 30 days after the webcast. About TKT Transkaryotic
Therapies, Inc. is a biopharmaceutical company primarily focused on
researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the
company markets Replagal(TM), an enzyme replacement therapy for
Fabry disease, and is developing treatments for Hunter syndrome and
Gaucher disease. In addition to its focus on rare diseases, TKT
intends to commercialize Dynepo(TM), its Gene- Activated(R)
erythropoietin product for anemia related to kidney disease, in the
European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe,
Canada and South America. Additional information about TKT is
available on the company's website at http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a
trademark of Sanofi-Aventis SA. Contact: Justine E. Koenigsberg
Senior Director, Corporate Communications (617) 349-0271
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications of TKT, +1-617-349-0271 Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Aug 2023 to Aug 2024